Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Tc-99m-aprotinin imaging in cardiac amyloidosis. Make an old tool new again?
Published in: Journal of Nuclear Cardiology
Access to document
10.1007/s12350-019-01917-3
document
Visual and semiquantitative assessment of cranial artery inflammation with FDG-PET/CT in giant cell arteritis
Published in: SEMINARS IN ARTHRITIS AND RHEUMATISM
Access to document
10.1016/j.semarthrit.2020.04.002
document
BACKGROUND AND AIM: Assessing cranial artery inflammation plays an important role in the diagnosis of cranial giant cell arteritis (C-GCA). However, current diagnostic tests are limited. The use of fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT imaging is an established tool for assessing large vessel inflammation but is currently not used for assessment of the cranial arteries. This study aimed to evaluate the accuracy of FDG-PET/CT in the diagnosis of biopsy proven C-GCA and its relation to clinical presentation. METHODS: This retrospective case control study included temporal artery biopsy...
Application of PET Tracers in Molecular Imaging for Breast Cancer
Published in: Current oncology reports
Access to document
10.1007/s11912-020-00940-9
document
Purpose of Review: Molecular imaging with positron emission tomography (PET) is a powerful tool to visualize breast cancer characteristics. Nonetheless, implementation of PET imaging into cancer care is challenging, and essential steps have been outlined in the international “imaging biomarker roadmap.” In this review, we identify hurdles and provide recommendations for implementation of PET biomarkers in breast cancer care, focusing on the PET tracers 2-[18F]-fluoro-2-deoxyglucose ([18F]-FDG), sodium [18F]-fluoride ([18F]-NaF), 16α-[18F]-fluoroestradiol ([18F]-FES), and [89Zr]-trastuzumab. Recent Findings: Technical validity of [18F]-FDG, [18F]-NaF, and [18F]-FES is established and supported by international...
Jorianne Boers, Erik F. J. de Vries, Andor W. J. M. Glaudemans, Geke A. P. Hospers, Carolina P. Schröder
Interim thymus and activation regulated chemokine versus interim F-18-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation
Published in: British Journal of Haematology
Access to document
10.1111/bjh.16514
document
Serum thymus and activation regulated chemokine (TARC) levels reflect classical Hodgkin lymphoma (cHL) disease activity and correspond with treatment response. We compared mid-treatment interim TARC (iTARC) with interim 18 F-fluorodeoxyglucose positron-emission tomography (iPET) imaging to predict modified progression-free survival (mPFS) in a group of 95 patients with cHL. High iTARC levels were found in nine and positive iPET in 17 patients. The positive predictive value (PPV) of iTARC for a 5-year mPFS event was 88% compared to 47% for iPET. The negative predictive value was comparable at 86%...
Molecular imaging in lymphoma beyond F-18-FDG-PET: understanding the biology and its implications for diagnostics and therapy
Published in: Lancet Haematology
Access to document
10.1016/S2352-3026(20)30065-X
document
Mature lymphoproliferative diseases are a heterogeneous group of neoplasms arising from different stages of B-cell and T-cell development. With improved understanding of the molecular processes in lymphoma and novel treatment options, arises a growing need for the molecular characterisation of tumours. Molecular imaging with single-photon-emission CT and PET using specific radionuclide tracers can provide whole-body information to investigate cancer biology, to evaluate phenotypic heterogeneity, to identify resistance to targeted therapy, and to assess the biodistribution of drugs in patients. In this Review, we evaluate the existing literature on...
Xaver U. Kahle, Filipe M. Montes de Jesus, Andor W. J. M. Glaudemans, Marjolijn N. Lub-de Hooge, Annelies Jorritsma-Smit, Wouter J. Plattel, Tom van Meerten, Arjan Diepstra, Anke van den Berg, Thomas C. Kwee, Walter Noordzij, Elisabeth G. E. de Vries, Marcel Nijland